TCGA-73-4677-01A-01R-1206-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
- ADIPOGENESIS+0.400
- PANCREAS_BETA_CELLS+0.380
- PROTEIN_SECRETION+0.380
- BILE_ACID_METABOLISM+0.360
- CHOLESTEROL_HOMEOSTASIS+0.320
- HEME_METABOLISM+0.310
- OXIDATIVE_PHOSPHORYLATION+0.310
- XENOBIOTIC_METABOLISM+0.310
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.610
- MYC_TARGETS_V2-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- INTERFERON_ALPHA_RESPONSE-0.390
- MYC_TARGETS_V1-0.330
- MITOTIC_SPINDLE-0.320
- INTERFERON_GAMMA_RESPONSE-0.260
- SPERMATOGENESIS-0.210
- MTORC1_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518177 | — | F | 0.880 |
| 2 | TCGA-91-6849-01A-11R-1949-07 | — | cohortA2 | 0.855 |
| 3 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.819 |
| 4 | TCGA-69-8253-01A-11R-2287-07 | — | cohortA2 | 0.819 |
| 5 | SRR6013578 | — | cohortA2 | 0.819 |
| 6 | SRR35579825 | — | B | 0.817 |
| 7 | TCGA-78-7633-01A-11R-2066-07 | — | cohortA2 | 0.808 |
| 8 | 60703_S134 | — | cohortA1 | 0.803 |
| 9 | 367ce5cb-52f9-4c87-aaa3-2808fca08bef | — | — | 0.792 |
| 10 | TCGA-44-2655-01A-01R-0946-07 | — | cohortA2 | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.440 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |